| 5.11 0.09 (1.79%) | 11-07 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 7.19  |
1-year : | 8.08 |
| Resists | First : | 6.15 |
Second : | 6.92 |
| Pivot price | 5.7 |
|||
| Supports | First : | 4.92 |
Second : | 4.1 |
| MAs | MA(5) : | 5.16 |
MA(20) : | 5.89 |
| MA(100) : | 5.27 |
MA(250) : | 6.51 |
|
| MACD | MACD : | -0.3 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 6.1 |
D(3) : | 5.9 |
| RSI | RSI(14): 31.1 |
|||
| 52-week | High : | 23.79 | Low : | 0.75 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ GBIO ] has closed above bottom band by 18.4%. Bollinger Bands are 23.2% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 5.14 - 5.18 | 5.18 - 5.21 |
| Low: | 4.85 - 4.89 | 4.89 - 4.93 |
| Close: | 5.04 - 5.11 | 5.11 - 5.17 |
Generation Bio Co., a genetic medicines company, develops therapies for the treatment of rare and prevalent diseases. The company provides a portfolio of programs, including programs for rare and prevalent diseases of the liver and retina. It also focuses on the diseases of skeletal muscle, central nervous system, and oncology. The company was formerly known as Torus Therapeutics, Inc. and changed its name to Generation Bio Co. in November 2017. Generation Bio Co. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.
Thu, 06 Nov 2025
Generation Bio Co. Reports Strategic Restructuring and Financial Highlights - TipRanks
Wed, 05 Nov 2025
Generation Bio Co reports results for the quarter ended September 30 - Earnings Summary - TradingView
Wed, 22 Oct 2025
Generation Bio CEO Geoff McDonough, MD to Step Down - citybiz
Wed, 22 Oct 2025
Geoff McDonough Steps Down as CEO of Generation Bio, Yalonda Howze Appointed Interim CEO - Quiver Quantitative
Mon, 18 Aug 2025
Generation Bio’s SWOT analysis: ctLNP tech stock faces pivotal moment - Investing.com
Wed, 13 Aug 2025
Generation Bio Stock Surged 31% Pre-Market Today – What’s Going On? - Stocktwits
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 7 (M) |
| Held by Insiders | 4.94e+006 (%) |
| Held by Institutions | 14.2 (%) |
| Shares Short | 152 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -7.032e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -2 % |
| Return on Assets (ttm) | 928.3 % |
| Return on Equity (ttm) | -21.1 % |
| Qtrly Rev. Growth | 2.123e+007 % |
| Gross Profit (p.s.) | -32.01 |
| Sales Per Share | -33.65 |
| EBITDA (p.s.) | -1.04764e+007 |
| Qtrly Earnings Growth | -10.9 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -81 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.16 |
| Price to Cash Flow | 1.61 |
| Dividend | 0 |
| Forward Dividend | 94890 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|